インフルエンザワクチンのヨーロッパ市場2020-2154

◆英語タイトル:EUROPE INFLUENZA VACCINE MARKET FORECAST 2020-2028
◆商品コード:INK20MY205
◆発行会社(リサーチ会社):Inkwood Research
◆発行日:2020年4月
◆ページ数:105
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:ヨーロッパ
◆販売価格オプション(消費税別)
Single UserUSD1,250 ⇒換算¥131,250見積依頼/購入/質問フォーム
Multi LicenseUSD1,500 ⇒換算¥157,500見積依頼/購入/質問フォーム
Enterprisewide PriceUSD2,000 ⇒換算¥210,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はInkwood Research社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Inkwood Research社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

【レポートの概要】

KEY FINDINGS The Europe influenza vaccine market is predicted to record a CAGR of 6.43% over the estimated period of 2020-2028. One of the crucial factors favoring the growth of the market is the high prevalence of influenza, leading to an increasing rate of immunization.

MARKET INSIGHTS
The European influenza vaccine market is further studied by dividing the region into countries such as Belgium, the UK, Russia, Poland, Germany, Italy, France, and the rest of Europe. In Russia, the influenza epidemic season of 2017-2018 was characterized by comparatively low morbidity and mortality due to the preventive measure of vaccination. 46.6% of the country’s population, were vaccinated before the influenza epidemic season of 2017-2018. Mass vaccination of the population has reduced the severity of the flu epidemic. In Belgium, there is a flu epidemic every winter, affecting around 3% to 10% of people and lasts for an average of eight weeks. The vaccination period is from mid-October to mid-December, so the flu vaccine may not be available in Jan-Feb. However, people who are vulnerable essentially need vaccination.
In countries like Poland, the number of flu cases was about 1.2 million in just Jan-Feb of 2020. Though this was less than 1.5 million in the analogous period of 2019, the number of cases accelerated about 200,000 per week in Feb. In Sweden, the 2018-2019 season was dominated by influenza A and was less intense than the previous five seasons. The laboratories in Sweden reported 13,757 cases, and 90% of these were influenza A. Due to these factors, the market looks promising in the region.

COMPETITIVE INSIGHTS
Novartis AG, Abbott, Sanofi, GlaxoSmithKline, F. Hoffmann-La Roch, etc. are some of the prominent companies operating in the region.
Our report offerings include:
• Explore key findings of the overall market
• Strategic breakdown of market dynamics (Drivers, Restraints, Opportunities, Challenges)
• Market forecasts for a minimum of 9 years, along with 3 years of historical data for all segments, sub-segments, and regions
• Market Segmentation cater to a thorough assessment of key segments with their market estimations
• Geographical Analysis: Assessments of the mentioned regions and country-level segments with their market share
• Key analytics: Porter’s Five Forces Analysis, Vendor Landscape, Opportunity Matrix, Key Buying Criteria, etc.
• Competitive landscape is the theoretical explanation of the key companies based on factors, market share, etc.
• Company profiling: A detailed company overview, product/services offered, SCOT analysis, and recent strategic developments

【レポートの目次】

1. RESEARCH SCOPE & METHODOLOGY
1.1. STUDY OBJECTIVES
1.2. SCOPE OF STUDY
1.3. METHODOLOGY
1.4. ASSUMPTIONS & LIMITATIONS
2. EXECUTIVE SUMMARY
2.1. MARKET SIZE & ESTIMATES `
2.2. MARKET OVERVIEW
3. MARKET DYNAMICS
3.1. PARENT MARKET ANALYSIS: VACCINE MARKET
3.2. MARKET DEFINITION
3.3. KEY DRIVERS
3.3.1. GOVERNMENT IMMUNIZATION PROGRAMS TO ERADICATE AILMENTS FROM THE SOCIETY
3.3.2. RISE IN THE CASES OF INFLUENZA
3.3.3. TECHNOLOGY ADVANCEMENT
3.4. KEY RESTRAINTS
3.4.1. HIGH COST OF DEVELOPMENT
3.4.2. LENGTHY PROCESS OF DEVELOPMENT
4. KEY ANALYTICS
4.1. KEY INVESTMENT INSIGHTS
4.2. PORTER’S FIVE FORCE ANALYSIS
4.2.1. BUYER POWER
4.2.2. SUPPLIER POWER
4.2.3. SUBSTITUTION
4.2.4. NEW ENTRANTS
4.2.5. INDUSTRY RIVALRY
4.3. OPPORTUNITY MATRIX
4.4. VENDOR LANDSCAPE
5. MARKET BY TYPE
5.1. QUADRIVALENT VACCINE
5.2. TRIVALENT VACCINE
6. MARKET BY TECHNOLOGY
6.1. EGG-BASED TECHNOLOGY
6.2. CELL-BASED TECHNOLOGY
7. MARKET BY AGE GROUP
7.1. PEDIATRIC AGE GROUP
7.2. ADULT AGE GROUP
8. MARKET BY DELIVERY MODE
8.1. INJECTION
8.2. NASAL SPRAY
9. GEOGRAPHICAL ANALYSIS
9.1. EUROPE
9.1.1. UNITED KINGDOM
9.1.2. GERMANY
9.1.3. FRANCE
9.1.4. ITALY
9.1.5. RUSSIA
9.1.6. BELGIUM
9.1.7. POLAND
9.1.8. REST OF EUROPE
10. COMPANY PROFILES
10.1. MERCK
10.2. NOVARTIS AG
10.3. PFIZER INC
10.4. SANOFI
10.5. BIODIEM
10.6. EMERGENT BIOSOLUTIONS
10.7. F. HOFFMANN-LA ROCHE LTD
10.8. GLAXOSMITHKLINE
10.9. ABBOTT
10.10. CSL LTD



【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[インフルエンザワクチンのヨーロッパ市場2020-2154]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆